Talc pleurodesis for malignant pleural effusions.

Talc pleurodesis for malignant pleural effusions. - Talc pleurodesis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009175

Enrollment

Registered

2012-10-24

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural effusion

Interventions

pleurodesis by intrapleural administration of 4 g of sterile talc.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: having uncontrolled and symptomatic pleural effusion, having proved to have malignant cells in pleural effusion by cytology or malignancies in pleural biopsy, and the ability to understand and sign informed consent forms.

Exclusion criteria

Exclusion criteria: having insufficient expansion of the lung after pleural fluid drainage (having trapped lung), inadequate lung function parameters, and severe heart failure.

Design outcomes

Primary

Measure	Time frame
Efficacy. We evaluate at 30, 90, and 180 days after talc pleurodesis by chest radiography.	—

Secondary

Measure	Time frame
Safety. We evaluated any complications requiring additional treatment or procedures within 30 days after talc pleurodesis.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026